ELI-002 7P + Tislelizumab for Pancreatic Cancer

This trial aims to determine if a new treatment combination is safe and effective for individuals with pancreatic cancer. It tests ELI-002 7P (an experimental treatment) with a chemotherapy regimen called mFOLFIRINOX, sometimes adding tislelizumab (an immunotherapy). The focus is on pancreatic ductal adenocarcinoma, a type of pancreatic cancer with a specific genetic mutation known as KRAS. Suitable candidates for this trial have pancreatic cancer with one of the specific KRAS mutations, and the disease must be resectable (removable by surgery). As a Phase 1 trial, the research focuses on understanding how the treatment works in people, offering participants the opportunity to be among the first to receive this new treatment.

Research shows that ELI-002 7P is promising in terms of safety. Studies have found that ELI-002 7P is generally well-tolerated and can activate strong immune responses, which is encouraging. In patients with certain types of cancer, including those with KRAS mutations, no major safety issues have been reported. This suggests that the treatment does not cause serious side effects for most people.

Tislelizumab, another treatment in the study, has already received approval for some cancer treatments, indicating it has passed safety checks for those uses. Although specific safety data for Tislelizumab in this particular trial is not yet available, its existing approval provides some confidence in its safety.

Unlike the standard treatments for pancreatic cancer, which often include chemotherapy regimens like mFOLFIRINOX, the combination of ELI-002 7P and Tislelizumab offers a novel approach. ELI-002 7P is a peptide-based vaccine designed to stimulate the immune system to target cancer-specific mutations, potentially enhancing the body's natural defenses against tumor cells. Tislelizumab, on the other hand, is an immune checkpoint inhibitor that helps the immune system recognize and attack cancer cells more effectively. Researchers are excited because this dual approach not only targets the cancer directly but also boosts the immune response, offering a fresh angle on fighting pancreatic cancer that could improve outcomes for patients.

Research has shown that ELI-002 7P triggers a strong immune response against pancreatic cancer with KRAS mutations, increasing specific T cell activity by an average of 145 times. This means the immune system becomes significantly more active against the cancer. In other studies, 99% of pancreatic cancer patients showed an immune reaction, and 88% responded to their tumor's mutation. In this trial, some participants will receive ELI-002 7P alongside mFOLFIRINOX.